Human medicines European public assessment report (EPAR): Qoyvolma, ustekinumab, Status: Opinion
On 27 March 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Qoyvolma, intended for the treatment of adults and children with plaque …